RIP kinase Inhibitor

RIPK1-IN-35 is a selective and orally active RIPK1 inhibitor with an IC₅₀ of 5.33 nM. RIPK1-IN-35 has a potent protective effect against necroptosis in both human and murine cells. RIPK1-IN-35 shows good therapeutic effects in both TNF-α-induced systemic inflammatory response syndrome and DSS (HY-116282C)-induced inflammatory bowel disease models. RIPK1-IN-35 can be used to the study of inflammatory diseases related to necroptosis.

RIPK1-IN-32 is a RIPK inhibitor with anti-inflammatory activity. RIPK1-IN-32 inhibits nitric oxide (NO) release with an IC₅₀ of 3.26 μM. RIPK1-IN-32 significantly alleviates acute liver injury associated with sepsis through the RIPK1/NF-κB/MAPK pathway, therefore preventing the nuclear translocation of p65 and c-fos, which results in reduced expression of TNF-α and IL-6. RIPK1-IN-32 can be used for the study of acute liver injury and sepsis.

GSK-872 (Standard) is the analytical standard of GSK-872 (HY-101872). This product is intended for research and analytical applications. GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC₅₀ of 1.8 nM, and inhibits kinase activity with an IC₅₀ of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury.

GSK963 (Standard) is the analytical standard of GSK963 (HY-103028A). This product is intended for research and analytical applications. GSK963 is a chiral, highly potent and selective inhibitor of RIP1 kinase, with an IC₅₀ of 29 nM. GSK963 is a selective and potent inhibitor of necroptosis in murine and human cells in vitro.

MLKL-IN-4 (compound 56) is a potent MLKL (Mixed lineage kinase domain-like protein) inhibitor. MLKL-IN-4 inhibits necroptosis in HT-29 cells and acts downstream of MLKL phosphorylation, with EC₅₀ of 82 nM. MLKL-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis.

GSK840 (Standard) is the analytical standard of GSK840 (HY-104021). This product is intended for research and analytical applications. GSK840 (GSK'840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC₅₀ of 0.9 nM, and inhibits kinase activity with an IC₅₀ of 0.3 nM.

GSK2982772 (Standard) is the analytical standard of GSK2982772 (HY-101760). This product is intended for research and analytical applications. GSK2982772 is a potent, orally active and ATP competitive RIP1 kinase inhibitor with IC₅₀ values of 16 nM and 20 nM for human and monkey RIP1, respectively.

RIPK1 ligand-Linker Conjugate-1 is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for RIPK1 (HY-175371) and a PROTAC linker (HY-175373), which recruits E3 ligases. RIPK1 ligand-Linker Conjugate-1 can be used for synthesis of PROTAC RIPK1 Degrader-1 (HY-175370).

RIP1 K_inase inhibitor 1 (Standard) is the analytical standard of RIP1 K_inase inhibitor 1 (HY-111409). This product is intended for research and analytical applications. RIP1 K_inase inhibitor 1 (compound 22) is a highly potent, orally available, and brain-penetrating RIP1 K_inase inhibitor (pK_i=9.04).

Necrostatin 2 (racemate) (Standard) is the analytical standard of Necrostatin 2 (racemate). This product is intended for research and analytical applications. Necrostatin 2 racemate (Nec-1S), the Necrostatin-1 (HY-15760) stable, is a potent and specific RIPK1 inhibitor lacking the IDO-targeting effect.

GSK481 (Standard) is the analytical standard of GSK481 (HY-100131). This product is intended for research and analytical applications. GSK481 is a highly potent, selective, and specific receptor interacting protein 1 (RIP1) kinase inhibitor with an IC50 of 1.3 nM, which inhibits Ser166 phosphorylation in wild-type human RIP1 (IC50=2.8 nM). GSK481 also exhibits excellent translation in the U937 cellular assay with an IC50 of 10 nM.

GSK3145095 (Standard) is the analytical standard of GSK3145095 (HY-111946). This product is intended for research and analytical applications. GSK3145095 is a RIP1 K_inase inhibitor with an IC₅₀ of 6.3 nM .

RIPK1-IN-24 is a receptor-interacting protein kinase 1 (RIPK1) inhibitor with an IC₅₀ value of 1.3 μM. RIPK1-IN-24 can be used for research on inflammatory diseases.

RIPA-56 (Standard) is the analytical standard of RIPA-56 (HY-101032). This product is intended for research and analytical applications. RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with an IC50 of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome.

ZBP1 PROTAC-1 is a PROTAC degrader targeting ZBP1, with a DC₅₀ of 81.52 nM. ZBP1 PROTAC-1 uses a DNA aptamer to specifically bind ZBP1, recruits the VHL E3 ubiquitin ligase, and induces ZBP1 degradation via the ubiquitin-proteasome pathway. ZBP1 PROTAC-1 can partially restore the viability of H1N1-infected cells. ZBP1 PROTAC-1 can be used in studies related to viral pneumonia and influenza A H1N1 virus infection.

Cl-Necrostatin-1 is a RIPK1 inhibitor. Cl-Necrostatin-1 can also inhibit TNF-α-induced necroptosis in Jurkat cells deficient in Fas-associated death domain protein (FADD; EC₅₀ = 180 nM), a modification that prevents caspase activation in response to death-domain receptor signaling. Cl-Necrostatin-1 can also reduce infarct size in a mouse model of middle cerebral artery occlusion (MCAO). Cl-Necrostatin-1 is used for research in cardiovascular and cerebrovascular diseases.

RIPK-IN-4 (Standard) is the analytical standard of RIPK-IN-4 (HY-107978). This product is intended for research and analytical applications. RIPK-IN-4 is a selective RIPK2 inhibitor with an IC₅₀ value of 3 nM. RIPK-IN-4 can be used for the research of inflammatory diseases.

GSK-872 hydrochloride (Standard) is the analytical standard of GSK-872 hydrochloride (HY-101872A). This product is intended for research and analytical applications. GSK-872 hydrochloride is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC₅₀ of 1.8 nM, and inhibits kinase activity with an IC₅₀ of 1.3 nM. GSK-872 hydrochloride decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury.

GSK583 (Standard) is the analytical standard of GSK583 (HY-100339). This product is intended for research and analytical applications. GSK583 is a highly potent, orally active and selective inhibitor of RIP2 Kinase, with IC50 of 5 nM. GSK583 inhibits both TNF-α and IL-6 production with an IC50 value of 200 nM.